Nasdaq:US$10.07 (-0.28) | HKEX:HK$16.52 (-0.08) | AIM:£1.75 (+0.01)
News & Presentations
Previous Article   |   Next Article
Presentations | 22 Jan 2022

ASCO GI 2022 | Phase 1/1b trial of fruquintinib in patients with advanced solid tumors: preliminary results of the dose expansion cohorts in refractory metastatic colorectal cancer